PACLITAXEL AND DOCETAXEL IN PROSTATE CANCER
- 29 June 2001
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 15 (3) , 525-545
- https://doi.org/10.1016/s0889-8588(05)70230-6
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancerUrology, 2001
- Phase I Clinical and Pharmacologic Study of 13-cis-Retinoic Acid, Interferon Alfa, and Paclitaxel in Patients With Prostate Cancer and Other Advanced MalignanciesJournal of Clinical Oncology, 1999
- Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell DeathJournal of Clinical Oncology, 1999
- Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven PolymerizationJournal of Biological Chemistry, 1997
- Taxol Differentially Modulates the Dynamics of Microtubules Assembled from Unfractionated and Purified β-Tubulin IsotypesBiochemistry, 1997
- Docetaxel.Journal of Clinical Oncology, 1995
- Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostateUrologic Oncology: Seminars and Original Investigations, 1995
- Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: Reversibility, ligand stoichiometry, and competitionBiochemistry, 1993
- Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivoThe Prostate, 1992
- Expression of Multidrug Resistance Gene in Human CancersJNCI Journal of the National Cancer Institute, 1989